AHA 2023 George Bakris shares the results of the KARDIA-1 trial, in which zilebesiran, a RNAi therapeutic targeting angiotensinogen, lowers blood pressure for up to 6 months with a single subcutaneous injection.
This video was recorded during the AHA Scientific Sessions 2023 in Philadelphia, PA, USA.
George L. Bakris, MD is Professor of Medicine and Director of the ASH Comprehensive Hypertension Center at the University of Chicago Medicine in Chicago, IL, USA.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
Florian Rader, MD
Michael Lincoff, MD
Deepak Gupta, MD